Download pdf New Celebrating Half a Century of Pioneering Excellence: EBMT Marks its 50th Anniversary The EBMT proudly commemorates its 50th anniversary, marking five decades of transformative advancements in the field of hematopoietic cell transplantation (HCT) and cellular therapy.
Download pdf Virtual twin to improve treatment with cancer immunotherapies An international team started the research project CERTAINTY in December 2023.
Download pdf The EBMT introduces its upgraded patient Registry to meet the needs of haematopoietic cell transplantation and cellular therapies After one year and a half of work, the EBMT launches its new and improved patient Registry database, co-funded by the European Union in a grant called EuroTraCTOR.
Download pdf Release of the first Handbook on CAR-T Cell in Europe The EBMT and EHA are proud to announce the release of the first-ever open-access book on CAR-T cells to be officially launched during the EBMT-EHA 4th European CAR-T Cell Meeting.
Download pdf EBMT trial demonstrates improvements in immunosuppressive treatment of patients with Severe Aplastic Anemia The results of the EBMT phase III RACE trial was published today by the New England Journal of Medicine.
Download pdf Hospital Privado Universitario de Córdoba is first to earn FACT-JACIE Stepwise Certification Hospital Privado Universitario de Córdoba, Argentina is first to earn Certificate of Completion for Step One under the FACT-JACIE International Standards for HCT Stepwise Accreditation Program.
Download pdf Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition The EBMT and the EHA announce a strategic partnership to empower Europe to become a global leader in the cellular therapy field for haematological diseases.
Download pdf German health insurance regulator directs centres to report commercial CAR-T treatments to the EBMT Registry The Gemeinsame Bundesausschuss (G-BA) published its directions on the treatment of German patients with CAR T-cell therapies.
Download pdf EBMT trial shows improvements in treatment of Severe Aplastic Anaemia The EBMT announced the results of the phase III RACE trial during EBMTs virtual 46th Annual Meeting.
Download pdf EBMT to track long-term outcome data for Yescarta®, a CAR T therapy for adults living with two types of aggressive non-Hodgkin lymphoma The EBMT announces a new collaboration with Kite, a Gilead Company, to study the long-term outcomes of patients treated with Yescarta® (axicabtagene ciloleucel), a chimeric antigen receptor T cell (CAR T) therapy.